Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEED NASDAQ:INBS NASDAQ:LYRA NASDAQ:NXGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEEDNanovibronix$1.36+2.8%$1.74$0.99▼$44.50$5.04M1.598.90 million shs530,823 shsINBSIntelligent Bio Solutions$2.32+1.1%$3.21$2.27▼$24.90$4.61M4.24488,491 shs10,002 shsLYRALyra Therapeutics$0.73-2.7%$0.77$0.31▼$37.50$1.30M0.6873,916 shs312 shsNXGLNexGel$0.59-3.7%$0.75$0.56▼$2.97$5.24M0.74275,680 shs59,919 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEEDNanovibronix+5.60%+13.79%-27.47%-54.79%+131,999,900.00%INBSIntelligent Bio Solutions-4.98%-6.53%-14.55%-63.24%-80.00%LYRALyra Therapeutics+2.74%+6.38%+41.51%-58.79%-85.71%NXGLNexGel+2.50%+4.20%+0.65%-51.57%-76.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEEDNanovibronix$1.36+2.8%$1.74$0.99▼$44.50$5.04M1.598.90 million shs530,823 shsINBSIntelligent Bio Solutions$2.32+1.1%$3.21$2.27▼$24.90$4.61M4.24488,491 shs10,002 shsLYRALyra Therapeutics$0.73-2.7%$0.77$0.31▼$37.50$1.30M0.6873,916 shs312 shsNXGLNexGel$0.59-3.7%$0.75$0.56▼$2.97$5.24M0.74275,680 shs59,919 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEEDNanovibronix+5.60%+13.79%-27.47%-54.79%+131,999,900.00%INBSIntelligent Bio Solutions-4.98%-6.53%-14.55%-63.24%-80.00%LYRALyra Therapeutics+2.74%+6.38%+41.51%-58.79%-85.71%NXGLNexGel+2.50%+4.20%+0.65%-51.57%-76.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEEDNanovibronix 1.00SellN/AN/AINBSIntelligent Bio Solutions 1.00SellN/AN/ALYRALyra Therapeutics 1.50ReduceN/AN/ANXGLNexGel 2.00Hold$2.00237.84% UpsideCurrent Analyst Ratings BreakdownLatest LYRA, NXGL, INBS, and FEED Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026FEEDNanovibronix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026INBSIntelligent Bio Solutions Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/12/2026NXGLNexGel Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$6.00 ➝ $2.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEEDNanovibronix$2.55M1.97N/AN/A$30.44 per share0.04INBSIntelligent Bio Solutions$3.05M1.52N/AN/A$4.07 per share0.57LYRALyra Therapeutics$600K2.16N/AN/A$8.86 per share0.08NXGLNexGel$11.42M0.46N/AN/A$0.60 per share0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEEDNanovibronix-$18.18M-$41.74N/AN/AN/A-712.30%-47.82%-38.06%N/AINBSIntelligent Bio Solutions-$10.57M-$14.82N/AN/AN/A-315.33%-200.68%-97.31%5/12/2026 (Estimated)LYRALyra Therapeutics-$93.43M-$19.15N/AN/AN/A-5,491.17%-1,010.91%-58.92%5/12/2026 (Estimated)NXGLNexGel-$3M-$0.38N/AN/AN/A-26.27%-56.90%-28.42%5/13/2026 (Estimated)Latest LYRA, NXGL, INBS, and FEED EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026NXGLNexGel-$0.07N/AN/AN/A$3.91 millionN/A5/12/2026N/AINBSIntelligent Bio Solutions$1.40N/AN/AN/A$7.20 millionN/A5/12/2026Q1 2026LYRALyra Therapeutics-$1.36N/AN/AN/AN/AN/A4/15/2026Q4 2025FEEDNanovibronixN/A-$20.00N/A-$20.00N/A$0.31 million3/31/2026Q4 2025NXGLNexGel-$0.09-$0.12-$0.03-$0.12$3.24 million$2.80 million2/12/2026Q2 2026INBSIntelligent Bio Solutions$0.40-$2.82-$3.22-$2.82$5.50 million$0.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFEEDNanovibronixN/AN/AN/AN/AN/AINBSIntelligent Bio SolutionsN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/ANXGLNexGelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEEDNanovibronixN/A1.090.74INBSIntelligent Bio SolutionsN/A2.372.26LYRALyra TherapeuticsN/A2.432.43NXGLNexGel0.151.470.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEEDNanovibronix16.39%INBSIntelligent Bio Solutions32.97%LYRALyra Therapeutics95.62%NXGLNexGel2.21%Insider OwnershipCompanyInsider OwnershipFEEDNanovibronix1.40%INBSIntelligent Bio Solutions1.27%LYRALyra Therapeutics3.25%NXGLNexGel20.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEEDNanovibronix203.70 million3.65 millionN/AINBSIntelligent Bio Solutions102.00 million1.98 millionNot OptionableLYRALyra Therapeutics501.78 million1.72 millionNo DataNXGLNexGel108.85 million7.03 millionNot OptionableLYRA, NXGL, INBS, and FEED HeadlinesRecent News About These CompaniesNEXGEL Secures Strategic Financing and Regenerative Portfolio LicenseApril 24, 2026 | theglobeandmail.comNexGel Receives Nasdaq Deficiency Notice Over Bid PriceApril 24, 2026 | tipranks.comNEXGEL, Inc. (NXGL) Q4 2025 Earnings Call TranscriptApril 21, 2026 | seekingalpha.comNEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ETApril 17, 2026 | globenewswire.comNEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity TransactionApril 15, 2026 | globenewswire.comNEXGEL reschedules shareholder call, revises financing planApril 14, 2026 | msn.comNexGel Inc (NXGL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...April 9, 2026 | finance.yahoo.comNEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity TransactionApril 8, 2026 | globenewswire.comNexGel, Inc Common Stock (NXGL) SEC FilingsApril 1, 2026 | nasdaq.comNEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with CelularityMarch 31, 2026 | globenewswire.comNEXGEL (NXGL) price target decreased by 66.67% to 2.04March 28, 2026 | msn.comNEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31stMarch 25, 2026 | finance.yahoo.comNEXGEL to pay $15 million for Celularity regenerative biomaterial portfolioMarch 17, 2026 | msn.comNEXGEL signs agreement to acquire regenerative biomaterial portfolioMarch 16, 2026 | msn.comNEXGEL, INC.: NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial ProductsMarch 12, 2026 | finanznachrichten.deCelularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway ...March 12, 2026 | finance.yahoo.comNEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial ProductsMarch 12, 2026 | globenewswire.comNEXGEL, INC.: NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial ProductsMarch 10, 2026 | finanznachrichten.deNexGel secures regenerative biomaterials portfolio from Celularity in landmark transactionMarch 10, 2026 | msn.comNEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial ProductsMarch 10, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLYRA, NXGL, INBS, and FEED Company DescriptionsNanovibronix NASDAQ:FEED$1.36 +0.04 (+2.80%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. ... NanoVibronix' catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.Intelligent Bio Solutions NASDAQ:INBS$2.32 +0.03 (+1.09%) As of 11:14 AM Eastern This is a fair market value price provided by Massive. Learn more.Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.Lyra Therapeutics NASDAQ:LYRA$0.73 -0.02 (-2.67%) As of 10:23 AM EasternLyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.NexGel NASDAQ:NXGL$0.59 -0.02 (-3.74%) As of 11:10 AM Eastern This is a fair market value price provided by Massive. Learn more.NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
